Randomized phase II study of TS-1 [S-1] therapy and TS-1+PSK [polysaccharide K] therapy against unresectable advanced gastric carcinoma and recurrent gastric carcinoma

Trial Profile

Randomized phase II study of TS-1 [S-1] therapy and TS-1+PSK [polysaccharide K] therapy against unresectable advanced gastric carcinoma and recurrent gastric carcinoma

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 22 Jan 2009

At a glance

  • Drugs Polysaccharide K (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Planned patient number changed from 120 to 13 as reported by ClinicalTrials.gov.
    • 16 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top